GlassScriptPhysician profile
Judith A Bergman
NPI 1184617128
$22,284.97
in general payments reported to CMS, 2019-2025
23 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,331 · 2022: $9,001 · 2023: $7,200 · 2024: $2,553 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,644 · Consulting Fee: $3,375 · Travel and Lodging: $1,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,644.03 |
| Consulting Fee | $3,375.00 |
| Travel and Lodging | $1,933.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $12,270.95 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $6,488.32 | 2021-2025 | Descovy, Biktarvy |
| Merck Sharp & Dohme LLC | $812.57 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Emd Serono, INC. | $436.94 | 2021-2024 | Serostim |
| Janssen Biotech, INC. | $418.73 | 2021-2023 | Symtuza, Imbruvica, Darzalex |
| Theratechnologies INC. | $339.25 | 2021-2023 | Trogarzo, Egrifta |
| Novo Nordisk INC | $335.01 | 2021-2025 | Wegovy |
| Abbvie INC. | $255.17 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $234.76 | 2022-2023 | Symtuza |
| Janssen Products, LP | $202.40 | 2021-2023 | Symtuza |
| Antares Pharma, INC. | $151.10 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Napo Pharmaceuticals INC | $96.77 | 2023-2024 | Mytesi |
| Abbott Laboratories | $47.77 | 2021-2023 | Freestyle Libre 2 |
| Halozyme INC | $38.57 | 2023 | |
| Pfizer INC. | $36.30 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $18.93 | 2021 | |
| Nalu Medical, INC. | $17.76 | 2021 | |
| Glaxosmithkline, LLC. | $16.94 | 2022 | |
| Tolmar, INC. | $15.07 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.28 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $13.95 | 2023 | |
| Astellas Pharma US INC | $12.20 | 2021 | |
| Oxford Immunotec USA INC | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Bergman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.